Q-omics provides the consensus-scored LEP profile across patient tissues and cancer cell-line models. LEP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LEP is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, LEP RNA expression shows 9,960 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight COAD, and BRCA as cancer lineages where LEP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LEP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LEP survival associations across molecular data types. LEP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LEP RNA expression–survival associations across cancer types. High LEP expression shows unfavorable associations in COAD, KIRC, ACC and UVM, but favorable associations in DLBC and LAML. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LEP RNA expression.
This table summarizes LEP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LEP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LEP shows lower tumor expression in BRCA, BLCA, STAD, KIRC and KICH and higher tumor expression in LUSC. The BRCA box plot shows higher LEP RNA expression in normal versus tumor tissue (log2 FC = −5.638, t-test p < 0.001).
This table shows molecular features associated with LEP in patient tissues and cancer cell lines. In patient samples, LEP shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LEP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
